What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Cancer
- Surgery
Hiromitsu Kumada mostly deals with Internal medicine, Gastroenterology, Virology, Hepatocellular carcinoma and Hepatitis C virus.
His Internal medicine study frequently draws connections between related disciplines such as Immunology.
His Gastroenterology research also works with subjects such as
- Surgery that intertwine with fields like Liver biopsy,
- Adverse effect together with Regimen.
His Virology course of study focuses on Genotype and Drug resistance and Polymerase chain reaction.
His research in Hepatocellular carcinoma intersects with topics in Cancer, Carcinoma, Retrospective cohort study and Oncology.
He studied Hepatitis C and Ribavirin that intersect with Combination therapy, Viral load and Anemia.
His most cited work include:
- Gene Expression in Fixed Tissues and Outcome in Hepatocellular Carcinoma (964 citations)
- Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. (641 citations)
- The long-term pathological evolution of chronic hepatitis C (542 citations)
What are the main themes of his work throughout his whole career to date?
Hiromitsu Kumada focuses on Internal medicine, Gastroenterology, Virology, Hepatocellular carcinoma and Hepatitis C virus.
His Internal medicine research integrates issues from Ribavirin and Immunology.
His Gastroenterology research includes themes of Chronic hepatitis, Adverse effect and Surgery, Retrospective cohort study.
Many of his studies on Virology involve topics that are commonly interrelated, such as Genotype.
The Hepatocellular carcinoma study combines topics in areas such as Carcinoma, Radiology, Oncology and Hazard ratio.
His Hepatitis C virus research includes elements of Interferon, Alpha interferon and Viral load.
He most often published in these fields:
- Internal medicine (58.76%)
- Gastroenterology (45.83%)
- Virology (32.76%)
What were the highlights of his more recent work (between 2016-2021)?
- Internal medicine (58.76%)
- Gastroenterology (45.83%)
- Hepatocellular carcinoma (30.60%)
In recent papers he was focusing on the following fields of study:
His scientific interests lie mostly in Internal medicine, Gastroenterology, Hepatocellular carcinoma, Hepatitis C virus and Virology.
His work focuses on many connections between Internal medicine and other disciplines, such as Genotype, that overlap with his field of interest in Young adult.
His biological study spans a wide range of topics, including Regimen, Retrospective cohort study, Nonalcoholic fatty liver disease, Fatty liver and Hepatitis B virus.
His work carried out in the field of Regimen brings together such families of science as Pibrentasvir, Immunology and Glecaprevir.
His studies deal with areas such as Multivariate analysis, Oncology and Hazard ratio as well as Hepatocellular carcinoma.
His works in Asunaprevir and Ribavirin are all subjects of inquiry into Virology.
Between 2016 and 2021, his most popular works were:
- Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma. (150 citations)
- Sustained virologic response by direct antiviral agents reduces the incidence of hepatocellular carcinoma in patients with HCV infection. (84 citations)
- A phase 1b trial of lenvatinib (LEN) plus pembrolizumab (PEM) in patients (pts) with unresectable hepatocellular carcinoma (uHCC). (80 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Cancer
- Surgery
The scientist’s investigation covers issues in Internal medicine, Gastroenterology, Hepatocellular carcinoma, Daclatasvir and Adverse effect.
His Internal medicine study integrates concerns from other disciplines, such as Surgery, Glecaprevir and Hepatitis C virus.
He combines subjects such as Clinical trial and Viral load with his study of Hepatitis C virus.
His Gastroenterology research is multidisciplinary, relying on both Pibrentasvir, Tolerability, HBeAg, Type 2 Diabetes Mellitus and Cohort.
His Hepatocellular carcinoma research incorporates elements of Retrospective cohort study, Carcinoma, Oncology and Hazard ratio.
His Daclatasvir research is multidisciplinary, incorporating perspectives in NS5A and Asunaprevir.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
